Question 1

What is Ianalumab?

Accepted Answer

Ianalumab is a Other.

Question 2

How often does Ianalumab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Ianalumab first tracked by Ergen?

Accepted Answer

First tracked on May 31, 2026.

Question 4

When was Ianalumab last mentioned in news?

Accepted Answer

Last active on Jun 01, 2026.

Question 5

What is Ianalumab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Ianalumab in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Ianalumab?

Accepted Answer

Novartis presents positive immunology data (May 31, 2026, 6 articles).

Question 8

How did the "Novartis presents positive immunology data" event impact Ianalumab?

Accepted Answer

Ianalumab is another drug from Novartis's pipeline, with interim results from Sjögren's Phase III extension study and Phase II data in systemic lupus erythematosus being presented. Positive results could accelerate its path to market.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.